Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab plus best supportive care versus best supportive care in platinum-failed incurable squamous cell carcinoma of the head and neck
2006-002472-17Phase 3Completed
- Sponsor
- Genmab
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Zalutumumab + Best Supportive Care with Best Supportive Care (2 arms). Primary endpoint: Overall survival. Started Jul 2006; status: completed.
02
Drugs
zalutumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2006-002472-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002472-17.